About Remus Pharma
Remus Pharma is a publicly listed company based in Austin (United States) founded in 2015. Remus Pharma is engaged in providing healthcare solutions globally. It operates on a Reseller / Distribution and Direct-to-Consumer (D2C) model. The company has 34 employees. Its Indian entity Remus Pharmaceuticals Limited reported revenue of ₹860 Cr. Remus Pharma offers products and services including Critical Care Products, Neurology Products, Cardiology Products, Diabetic Products, and Generics. Its focus areas include Pharmaceuticals and Generic Drugs. Its competitors include Pfizer, LabConnect and Matchpoint Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Remus Pharma, along with its group of companies, is focused on marketing pharmaceutical products with specialization in Critical Care, Neurology, Cardiology, and Diabetic categories. Products are distributed through a diverse global channel to ensure accessibility. Emphasis is placed on quality standards, regulatory compliance, and clinical trials for safety. Affordable generics and niche demand-specific products are developed, alongside efforts to secure off-patent molecules for market advantage. Operations span across multiple countries with a commitment to evolving the healthcare landscape.
- Headquarters Austin, United States
- Employees 34
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website remuspharma.com
- Social LinkedIn
- Legal Name Remus Pharmaceuticals Ltd.
- Market Cap₹966 Cr
REMUS-SM · NSE
- Share Price₹810.90
-1.11% today
- Revenue₹854 Cr
FY 2025-26 · +37.6% YoY
- EBITDA₹56.69 Cr
Margin 6.6%
- Net Profit₹36.99 Cr
FY 2025-26 · +28.0% YoY
- P/E (TTM)26.2x
P/B 2.8x
- Employee Count34
Associated legal entities of Remus Pharma
Remus Pharma is associated with 2 registered companies on The Company Check; the primary company is Remus Pharmaceuticals Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Remus Pharmaceuticals Limited Listed CIN L24232GJ2015PLC084536 | Active | 21 Sep 2015 | Ahmedabad, Gujarat | ₹860 Cr | 34 | 10 | View details |
| Remus Pharmaceuticals CIN U24232GJ2015PLC084536 | 21 Sep 2015 | Ahmedabad, Gujarat, India | View details |
Products & Services of Remus Pharma
Remus Pharma offers a comprehensive portfolio of products and services, including Critical Care Products, Neurology Products, Cardiology Products, Diabetic Products, and Generics.
Critical care products are developed for urgent medical needs.
Neurology products are offered for brain-related health issues.
Cardiology products are provided for heart health management solutions.
Diabetic products are designed for managing blood sugar levels.
Affordable generics are produced for accessible healthcare solutions.
Board of directors of Remus Pharmaceuticals Limited (Remus Pharma)
Remus Pharmaceuticals Limited is the primary company behind Remus Pharma. The board of Remus Pharmaceuticals Limited currently have 8 directors; the longest-serving is Swapnil Jatinbhai Shah, appointed in 2015. 7 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Swapnil Jatinbhai Shah DIN 05259821 | Director | 21 Sep 2015 | 11 yrs 1 mo | Remus Pharmaceuticals Limited |
| Roma Vinodbhai Shah DIN 07214632 | Whole-time director | 21 Sep 2015 | 11 yrs 1 mo | Remus Pharmaceuticals Limited |
| Arpit Deepakkumar Shah DIN 07214641 | Managing Director | 21 Sep 2015 | 11 yrs 1 mo | Remus Pharmaceuticals Limited |
| Anar Swapnil Shah DIN 06895297 | Director | 30 Dec 2020 | 5 yrs 10 mo | Remus Pharmaceuticals Limited |
| Sanjana Sanjeev Shah DIN 09811689 | Director | 06 Jan 2023 | 3 yrs 10 mo | Remus Pharmaceuticals Limited |
| Balwant Purohit DIN 09806032 | Director | 06 Jan 2023 | 3 yrs 10 mo | Remus Pharmaceuticals Limited |
| Vishrut Chandramauli Pathak DIN 03278445 | Director | 06 Jan 2023 | 3 yrs 10 mo | Remus Pharmaceuticals Limited |
| Ashutosh Naginbhai Valani DIN 00559688 | Additional Director | 02 Sep 2026 | 2 mo | Remus Pharmaceuticals Limited |
IPO & Listings of Remus Pharma
Remus Pharma is a publicly listed company on the NSE with ticker symbol REMUS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date29 May 2023
- Listed onNSE: REMUS
- Listed entityRemus Pharmaceuticals Ltd.
- Exchange sectorHealth technology
- ISININE0O5T01011
- Share price₹977.55 (+5.68% on the day) · 2026-10-14
- Market capitalisation₹1,098 Cr
- Price to earnings31.1
- EPS (diluted, trailing year)₹31.40
- Dividend yield0.11%
- Volume (last session)5,100
Financials of Remus Pharma
Exchange-reported figures of Remus Pharmaceuticals Limited, the listed company behind Remus Pharma (NSE: REMUS-SM).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Income statement | |||
| Revenue | 854 | 620 | 213 |
| Revenue growth | +37.6% | +191.3% | - |
| EBITDA | 56.69 | 45.69 | 28.96 |
| EBITDA margin | +6.6% | +7.4% | +13.6% |
| Profit before tax | 59.16 | 47.34 | 30.17 |
| Net profit | 36.99 | 28.91 | 20.52 |
| Net profit margin | +4.3% | +4.7% | +9.6% |
| EPS (₹) | 39.19 | 49.35 | 139.59 |
| Balance sheet | |||
| Total assets | 415 | 306 | 190 |
| Net worth | 351 | 256 | 158 |
| Total debt | 27.07 | 22.98 | 14.23 |
| Cash & bank | 12.88 | 8.14 | 13.85 |
| Net working capital | 146 | 118 | 80.14 |
| Cash flow | |||
| Cash from operations | 18.16 | 6.98 | 3.60 |
| Cash from investing | (15.03) | (10.55) | (8.94) |
| Cash from financing | 1.47 | 6.07 | 24.37 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 93.99 | 79.16 | 63.94 | 45.03 | 24.72 | 18.42 | 11.92 |
| Revenue growth | +18.7% | +23.8% | +42.0% | +82.2% | +34.2% | +54.5% | - |
| EBITDA | 29.72 | 25.98 | 21.00 | 10.55 | 4.14 | 0.80 | 0.38 |
| EBITDA margin | +31.6% | +32.8% | +32.8% | +23.4% | +16.8% | +4.3% | +3.2% |
| Profit before tax | 33.23 | 26.64 | 22.35 | 11.42 | 4.62 | 1.40 | 1.08 |
| Net profit | 24.71 | 19.75 | 16.62 | 8.51 | 3.43 | 0.97 | 0.79 |
| Net profit margin | +26.3% | +25.0% | +26.0% | +18.9% | +13.9% | +5.3% | +6.6% |
| EPS (₹) | 20.96 | 33.79 | 113.06 | 78.37 | 34.34 | 1,059.50 | 811.60 |
| Balance sheet | |||||||
| Total assets | 333 | 247 | 158 | 27.35 | 6.77 | 3.42 | 2.46 |
| Net worth | 326 | 242 | 154 | 19.14 | 6.58 | 3.14 | 2.02 |
| Total debt | 6.20 | 4.31 | 4.12 | 7.95 | 0.19 | 0.28 | 0.36 |
| Cash & bank | 3.82 | 4.37 | 10.84 | 3.04 | 1.15 | 0.83 | 1.20 |
| Net working capital | 49.36 | 43.70 | 34.68 | 4.04 | (1.39) | (0.10) | 1.92 |
| Cash flow | |||||||
| Cash from operations | 22.30 | 15.59 | 6.31 | 5.31 | 5.04 | (0.12) | 1.30 |
| Cash from investing | (26.33) | (12.42) | (47.24) | (15.19) | (4.55) | (0.13) | (0.56) |
| Cash from financing | 0.13 | (1.42) | 41.63 | 11.77 | (0.17) | (0.11) | 0.06 |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Revenue | 854 | 620 | 213 |
| Revenue growth | +37.6% | +191.3% | - |
| Other income | 6.70 | 4.98 | 2.83 |
| Total expenses | 797 | 575 | 184 |
| Employee cost | 0.00 | 13.11 | 7.32 |
| EBITDA | 56.69 | 45.69 | 28.96 |
| EBITDA margin | +6.6% | +7.4% | +13.6% |
| Depreciation | 2.76 | 1.87 | 1.12 |
| Interest | 1.47 | 1.46 | 0.50 |
| Profit before tax | 59.16 | 47.34 | 30.17 |
| Tax | 12.99 | 8.92 | 5.89 |
| Net profit | 36.99 | 28.91 | 20.52 |
| Net profit margin | +4.3% | +4.7% | +9.6% |
| EPS (₹) | 39.19 | 49.35 | 139.59 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 11.78 | 5.89 | 1.47 |
| Reserves & surplus | 339 | 250 | 156 |
| Shareholders' funds (net worth) | 351 | 256 | 158 |
| Minority interest | 36.74 | 26.69 | 17.52 |
| Secured loans | 21.37 | 19.26 | 9.99 |
| Unsecured loans | 5.70 | 3.72 | 4.24 |
| Total debt | 27.07 | 22.98 | 14.23 |
| Total liabilities | 415 | 306 | 190 |
| Assets | |||
| Gross block | 24.36 | 19.27 | 15.86 |
| Net block | 18.27 | 15.76 | 13.79 |
| Capital work in progress | 8.50 | 0.06 | 0.01 |
| Investments | 275 | 186 | 105 |
| Inventories | 72.06 | 51.56 | 43.11 |
| Sundry debtors | 140 | 108 | 115 |
| Cash & bank balances | 12.88 | 8.14 | 13.85 |
| Loans & advances | 52.33 | 53.64 | 39.94 |
| Total current assets | 277 | 221 | 212 |
| Total current liabilities | 131 | 104 | 132 |
| Net working capital | 146 | 118 | 80.14 |
| Total assets | 415 | 306 | 190 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Opening cash | 7.22 | 4.73 | 7.84 |
| Net cash from operating activities | 18.16 | 6.98 | 3.60 |
| Net cash from investing activities | (15.03) | (10.55) | (8.94) |
| Net cash from financing activities | 1.47 | 6.07 | 24.37 |
| Net change in cash | 4.60 | 2.50 | 19.03 |
| Closing cash | 12.88 | 8.14 | 13.85 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Growth | |||
| Sales growth | +37.6% | +191.3% | - |
| EBITDA growth | +24.1% | +57.8% | - |
| PBT growth | +25.0% | +56.9% | +9997.0% |
| Net income growth | +28.0% | +40.9% | - |
| Profitability & leverage | |||
| Net income margin | +5.4% | +6.2% | +11.4% |
| Return on capital employed | - | +21.6% | +17.8% |
| Return on net worth | - | +18.6% | +15.4% |
| Debt / equity | - | 0.09 | 0.09 |
| Long-term debt / equity | - | 0.02 | 0.03 |
| Interest cover | 2.73 | 3.33 | 1.80 |
| Efficiency & per share | |||
| Fixed asset turnover | - | 35.34 | 13.43 |
| Inventory turnover | - | 13.11 | 4.94 |
| Debtors turnover | - | 5.56 | 1.85 |
| EPS (₹) | 39.19 | 49.35 | 139.59 |
| Dividend per share (₹) | 0.50 | 1.50 | 6.00 |
| Book value per share (₹) | 0.00 | 434.40 | 1,072.72 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 93.99 | 79.16 | 63.94 | 45.03 | 24.72 | 18.42 | 11.92 |
| Revenue growth | +18.7% | +23.8% | +42.0% | +82.2% | +34.2% | +54.5% | - |
| Other income | 6.84 | 2.91 | 2.81 | 1.58 | 0.72 | 0.81 | 0.85 |
| Total expenses | 64.27 | 53.18 | 42.94 | 34.48 | 20.58 | 17.62 | 11.54 |
| Employee cost | 0.00 | 9.17 | 6.51 | 5.47 | 3.42 | 2.95 | 2.86 |
| EBITDA | 29.72 | 25.98 | 21.00 | 10.55 | 4.14 | 0.80 | 0.38 |
| EBITDA margin | +31.6% | +32.8% | +32.8% | +23.4% | +16.8% | +4.3% | +3.2% |
| Depreciation | 2.75 | 1.87 | 1.12 | 0.48 | 0.15 | 0.18 | 0.11 |
| Interest | 0.58 | 0.38 | 0.34 | 0.23 | 0.09 | 0.03 | 0.04 |
| Profit before tax | 33.23 | 26.64 | 22.35 | 11.42 | 4.62 | 1.40 | 1.08 |
| Tax | 8.52 | 6.74 | 5.73 | 2.91 | 1.18 | 0.35 | 0.29 |
| Net profit | 24.71 | 19.75 | 16.62 | 8.51 | 3.43 | 0.97 | 0.79 |
| Net profit margin | +26.3% | +25.0% | +26.0% | +18.9% | +13.9% | +5.3% | +6.6% |
| EPS (₹) | 20.96 | 33.79 | 113.06 | 78.37 | 34.34 | 1,059.50 | 811.60 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 11.78 | 5.89 | 1.47 | 1.09 | 1.00 | 0.01 | 0.01 |
| Reserves & surplus | 314 | 236 | 152 | 18.05 | 5.58 | 3.13 | 2.01 |
| Shareholders' funds (net worth) | 326 | 242 | 154 | 19.14 | 6.58 | 3.14 | 2.02 |
| Secured loans | 4.33 | 2.14 | 1.65 | 2.30 | 0.19 | 0.28 | 0.36 |
| Unsecured loans | 1.87 | 2.17 | 2.47 | 5.65 | 0.00 | 0.00 | 0.00 |
| Total debt | 6.20 | 4.31 | 4.12 | 7.95 | 0.19 | 0.28 | 0.36 |
| Total liabilities | 333 | 247 | 158 | 27.35 | 6.77 | 3.42 | 2.46 |
| Assets | |||||||
| Gross block | 13.23 | 10.51 | 7.14 | 3.50 | 0.79 | 0.72 | 0.65 |
| Net block | 7.32 | 7.01 | 5.06 | 2.54 | 0.31 | 0.39 | 0.50 |
| Capital work in progress | 0.06 | 0.06 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 |
| Investments | 297 | 209 | 127 | 20.62 | 3.07 | 0.07 | 0.00 |
| Inventories | 2.75 | 2.12 | 1.89 | 0.29 | 1.59 | 1.15 | 0.44 |
| Sundry debtors | 23.75 | 15.63 | 14.60 | 4.85 | 2.92 | 3.60 | 1.63 |
| Cash & bank balances | 3.82 | 4.37 | 10.84 | 3.04 | 1.15 | 0.83 | 1.20 |
| Loans & advances | 35.78 | 31.79 | 21.55 | 3.17 | 2.04 | 1.91 | 1.50 |
| Total current assets | 66.10 | 53.91 | 48.88 | 11.35 | 7.70 | 7.49 | 4.77 |
| Total current liabilities | 16.74 | 10.21 | 14.20 | 7.31 | 9.09 | 7.59 | 2.85 |
| Net working capital | 49.36 | 43.70 | 34.68 | 4.04 | (1.39) | (0.10) | 1.92 |
| Total assets | 333 | 247 | 158 | 27.35 | 6.77 | 3.42 | 2.46 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 3.46 | 1.71 | 1.01 | 1.15 | 0.83 | 1.20 | 0.39 |
| Net cash from operating activities | 22.30 | 15.59 | 6.31 | 5.31 | 5.04 | (0.12) | 1.30 |
| Net cash from investing activities | (26.33) | (12.42) | (47.24) | (15.19) | (4.55) | (0.13) | (0.56) |
| Net cash from financing activities | 0.13 | (1.42) | 41.63 | 11.77 | (0.17) | (0.11) | 0.06 |
| Net change in cash | (3.90) | 1.75 | 0.70 | 1.89 | 0.32 | (0.37) | 0.81 |
| Closing cash | 3.82 | 4.37 | 10.84 | 3.04 | 1.15 | 0.83 | 1.20 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +18.7% | +23.8% | +42.0% | +82.2% | +34.2% | +54.5% | - |
| EBITDA growth | +14.4% | +23.7% | +99.1% | +154.8% | +417.5% | +110.5% | - |
| PBT growth | +24.7% | +19.2% | +95.7% | +147.2% | +230.0% | +29.6% | +9997.0% |
| Net income growth | +25.1% | +18.8% | +95.3% | +148.1% | +253.6% | +22.8% | - |
| Revenue CAGR (3Y) | +27.8% | +47.4% | +51.4% | +55.7% | - | - | - |
| EBITDA CAGR (3Y) | +41.2% | +84.5% | +197.2% | +202.8% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +26.3% | +25.1% | +26.0% | +18.9% | +13.9% | +5.7% | +6.6% |
| Return on capital employed | - | +13.3% | +24.5% | +68.2% | +92.3% | +49.0% | +45.9% |
| Return on net worth | - | +10.1% | +19.3% | +66.1% | +70.6% | +41.1% | +40.1% |
| Debt / equity | - | 0.02 | 0.07 | 0.32 | 0.05 | 0.12 | 0.18 |
| Long-term debt / equity | - | 0.02 | 0.06 | 0.28 | 0.03 | 0.09 | 0.14 |
| Interest cover | 2.15 | 1.58 | 1.71 | 2.28 | 2.26 | 4.84 | 14.81 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 8.97 | 12.02 | 20.99 | 32.74 | 26.89 | 18.34 |
| Inventory turnover | - | 39.48 | 58.66 | 47.90 | 18.04 | 23.17 | 27.09 |
| Debtors turnover | - | 5.24 | 6.57 | 11.59 | 7.58 | 7.04 | 7.31 |
| EPS (₹) | 20.96 | 33.79 | 113.06 | 78.37 | 34.34 | 1,059.50 | 811.60 |
| Dividend per share (₹) | 0.50 | 1.50 | 6.00 | 2.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 411.24 | 1,044.56 | 176.36 | 65.78 | 3,143.70 | 2,020.30 |
Competitors of Remus Pharma
Remus Pharma has 3 listed competitors in our database, 3 of them funded. They include Pfizer, LabConnect and Matchpoint Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pfizer.com | 1849 | New York, United States | $8M | Pharmaceutical products for treating multiple diseases are provided. | ||
| labconnect.com | 2002 | Johnson, United States | $28.5M | Laboratory testing, clinical trial research, and biopharma services are provided. | ||
| matchpointtx.com | 2021 | Cambridge, United States | $100M | 27 | Small molecule medicine development and analytics services are provided. |
Detailed competitors of Remus Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Remus Pharma
The website of Remus Pharma (remuspharma.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▼ 9% vs previous month
Websites whose visitors overlap most with Remus Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| chavdainfra.com | 99% | 3K | #4,084,566 | View details | |
| dharmajcrop.com | 86% | 2.8K | #6,308,972 | View details | |
| amanta.co.in | 86% | 2K | #7,642,340 | View details | |
| jeksonvision.com | 30% | 4.7K | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Remus Pharma (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Remus Pharma
Complete news archive for Remus Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Remus Pharma
Remus Pharma was founded in 2015.
Remus Pharma is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Remus Pharma has 34 employees.
The primary company behind Remus Pharma, Remus Pharmaceuticals Limited, reported revenue of ₹860 Cr for FY 2026, up 38% year on year.
Remus Pharma, along with its group of companies, is focused on marketing pharmaceutical products with specialization in Critical Care, Neurology, Cardiology, and Diabetic categories. Products are distributed through a diverse global channel to ensure accessibility. Emphasis is placed on quality standards, regulatory compliance, and clinical trials for safety. Affordable generics and niche demand-specific products are developed, alongside efforts to secure off-patent molecules for market advantage. Operations span across multiple countries with a commitment to evolving the healthcare landscape.
Remus Pharma's top competitors include Pfizer, LabConnect and Matchpoint Therapeutics.
Remus Pharma offers Critical Care Products, Neurology Products, Cardiology Products, Diabetic Products, and Generics.
Yes, Remus Pharma is publicly traded on NSE under the ticker symbol REMUS.
Remus Pharma operates through Remus Pharmaceuticals Limited.
The legal entities of Remus Pharma currently have 10 directors, including Swapnil Jatinbhai Shah, Roma Vinodbhai Shah, Arpit Deepakkumar Shah and others.